(Q77493115)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797017%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797017%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797017%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797017%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797017%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

49 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797017%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

S45-52; discussion S73-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797017%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1006048722559

6 December 2019

exact match

0 references

cites work

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

A dose response evaluation of delta-1-testololactone in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Inhibition of Peripheral Aromatization of Androstenedione to Estrone in Postmenopausal Women with Breast Cancer Using Δ1Testololactone*

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Aromatase inhibitors and their potential clinical significance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Novel aromatase and 5 alpha-reductase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Novel irreversible aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using high-performance liquid chromatography-mass spectrometry

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Mechanisms of action of endocrine treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Importance of estrogen sulfates in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021

Analysis of the aromatase cytochrome P450 gene in human breast cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006048722559

7 January 2021